Agrippal S1

Agrippal S1 vaccine is a suspension for injection, supplied in single-use, ready-to-use syringe doses of 0.5 ml capacity, eliminating the loss of sterility of the drug. The syringe is equipped with a risk for the introduction of a child’s dose and a double sticker to account for vaccination ^{[3] [2]} .

Agrippal S1 contains hemagglutinin and neuraminidase of two influenza viruses of type “A” and one of type “B”. The antigenic composition of the vaccine is updated annually in accordance with the recommendations of the World Health Organization ^[2] .

The vaccine may contain the following substances in residual amounts: chicken protein, kanamycin and neomycin, formaldehyde, cetyltrimethylammonium bromide (CTAB), polysorbate 80, which are used in the manufacture of the vaccine. Mertiolate does not contain ^[4] .

It is an immunostimulant, forms a specific immunity to influenza viruses ^[2] .

Influenza prophylaxis in adults and children over 6 months.

Hypersensitivity to the components of the vaccine, including the protein of chicken eggs.

Vaccination should be delayed in acute infectious diseases or chronic exacerbations. Vaccinations are done after recovery or during remission. In mild forms of acute respiratory viral infections and acute respiratory infections, vaccinations are given immediately after normalization of body temperature ^[4] .

Allergic reactions , local reactions, malaise, headache, fever, sweating, myalgia , arthralgia may occur; in very rare cases, as with any vaccination, the development of minor neurological complications is possible ^[2] .

The vaccine is administered intramuscularly or subcutaneously. Do not administer intravenously.

Dosage ^[4] :

• children from 6 months to 3 years - 0.25 ml once;
• children from 3 years old, healthy adults and adolescents - 0.5 ml once;
• children under 3 years old who have not been vaccinated in previous years are recommended a double vaccination of 0.25 ml with an interval of 1 month;
• persons with immunodeficiency states - twice with an interval of 1 month.

Agrippal S1 provides the formation of a protective level of specific antibodies in 98% of vaccinees. When using the vaccine, local reactions (soreness and redness at the injection site) and isolated cases of general reactions were noted: fever, malaise, headache. All symptoms disappear on their own within 1-2 days. According to the GISK them. L.A. Tarasevich during the time of mass use in Russia did not reveal a single case of serious side effects after vaccination with this drug ^[3] .

Being a subunit vaccine, Agrippal belongs to the most non-reactogenic vaccines, which are less likely to give side effects, are well tolerated, but their immune response is weaker ^[4] .

• Agrippal S1® - registration certificate P N012054 / 01 (Russian) . Radar . Date of treatment January 14, 2019.
• Agrippal S1® (Agrippal S1®) (Russian) . Radar (July 31, 2000). - Description of the drug. Date of treatment January 14, 2019.
• Agrippal® SI is a trivalent inactivated purified subunit vaccine of the third generation for the prevention of influenza (Russian) . Epidemiologist.ru . Date of treatment January 14, 2019.
• Agrippal is a type A and B flu vaccine . The vaccine Agrippal promotes the development of immunity in humans against the influenza virus types A and B (Russian) . Clinic "Family" . Date of treatment January 14, 2019.
• Flu vaccines 2018 (rus.) (Pdf). Federal budgetary health institution "Center for Hygiene and Epidemiology in the Moscow Region . " Date of treatment January 14, 2019.